Want to see DMRA full AI Analyst Report?
DMRA Stock Chart & Stats
$26.60
-$0.21(-3.82%)
At close: 4:00 PM EST
$26.60
-$0.21(-3.82%)
Day’s Range― - ―
52-Week Range$2.45 - $38.33
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.26M
Market Cap
$1.85B
Enterprise Value$786.91M
Total Cash (Recent Filing)$532.90M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Aug 05, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-152.08
Shares Outstanding61,553,192
10 Day Avg. Volume9,383,356
30 Day Avg. Volume5,257,093
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.00
P/FCF Ratio-4.54
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.57K
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$42.67Price Target Upside60.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.9
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong SolvencyMinimal debt reduces solvency risk and gives the company durable financial flexibility common among early-stage biotechs. With low fixed obligations, management can prioritize R&D and strategic deals rather than servicing debt, preserving optionality across funding cycles.
Improving Cash Burn TrendA materially smaller operating cash outflow in 2025 signals improved cost discipline or program prioritization. While still negative, a lower burn rate extends runway between financings, reducing near-term dilution risk and giving the company more time to advance clinical milestones.
Strengthened Financial LeadershipPromoting an experienced internal finance leader with public biotech and audit experience increases governance continuity post-acquisition. Strong, knowledgeable financial stewardship supports reliable reporting, financing execution, and capital allocation through multi-stage development.
Bears Say
Pre-revenue Business ModelAbsence of revenue means the company depends entirely on external funding and progress of pipeline assets. Without product sales, operating sustainability hinges on successful R&D outcomes or partnerships, a fundamental risk until commercialization is achieved.
Large And Widening Net LossesA steep increase in net loss indicates significant cash consumption or one-off costs (e.g., acquisition or program spend). Large, volatile losses heighten future financing needs, raise dilution risk, and amplify execution pressure on management to demonstrate tangible clinical or partnering progress.
Negative Cash Generation; Funding DependenceConsistent negative operating and free cash flows mean the company cannot self-fund operations. Continued reliance on external capital subjects the business to market conditions and potential dilution, making long-term progress contingent on successful financings or strategic collaborations.
Damora Therapeutics News
DMRA FAQ
What was Damora Therapeutics’s price range in the past 12 months?
Damora Therapeutics lowest stock price was $2.45 and its highest was $38.33 in the past 12 months.
What is Damora Therapeutics’s market cap?
Damora Therapeutics’s market cap is $1.85B.
When is Damora Therapeutics’s upcoming earnings report date?
Damora Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 31 days.
How were Damora Therapeutics’s earnings last quarter?
Damora Therapeutics released its earnings results on May 12, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.232.
Is Damora Therapeutics overvalued?
According to Wall Street analysts Damora Therapeutics’s price is currently Undervalued.
Does Damora Therapeutics pay dividends?
Damora Therapeutics does not currently pay dividends.
What is Damora Therapeutics’s EPS estimate?
Damora Therapeutics’s EPS estimate is -0.43.
How many shares outstanding does Damora Therapeutics have?
Damora Therapeutics has 61,553,192 shares outstanding.
What happened to Damora Therapeutics’s price movement after its last earnings report?
Damora Therapeutics reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went up 4.634%.
Which hedge fund is a major shareholder of Damora Therapeutics?
Currently, no hedge funds are holding shares in DMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Damora Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.67 (60.40% Upside)
$42.67 (60.40% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.34%
12-Months-Change
Fundamentals
Return on Equity
-122.61%
Trailing 12-Months
Asset Growth
3384.82%
Trailing 12-Months
Company Description
Damora Therapeutics
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
DMRA Stock 12 Month Forecast
Average Price Target
$42.67
▲(60.40% Upside)
Technical Analysis
Ownership Overview
15.94% Insiders
10.72% Mutual Funds
61.80% Other Institutional Investors
6.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---